Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.

Date publication

mai 2018

Journal

Journal of neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MOULIN Thierry

Tous les auteurs :
Gilliot S, Sibon I, Mas JL, Moulin T, Béjot Y, Cordonnier C, Giroud M, Odou P, Bordet R, Vivien D, Leys D,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29549467

Résumé

Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) at stroke onset. ACE-Is and ARBs have neuroprotective properties in animal models.

Mots clés

Cerebral ischemia, Hemorrhagic transformation, Ischemic stroke, Mechanical thrombectomy, Neuroprotection, Outcome, Thrombolysis

Référence

J Neurol. 2018 May;265(5):1166-1173